Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism Is Associated With Progressive Atherosclerosis and Incident Cardiovascular Disease

Objective—The enzyme heme oxygenase-1 (HO-1) exerts cytoprotective effects in response to various cellular stressors. A variable number tandem repeat polymorphism in the HO-1 gene promoter region has previously been linked to cardiovascular disease. We examined this association prospectively in the general population. Approach and Results—Incidence of stroke, myocardial infarction, or vascular death was registered between 1995 and 2010 in 812 participants of the Bruneck Study aged 45 to 84 years (49.4% males). Carotid atherosclerosis progression was quantified by high-resolution ultrasound. HO-1 variable number tandem repeat length was determined by polymerase chain reaction. Subjects with ≥32 tandem repeats on both HO-1 alleles compared with the rest of the population (recessive trait) featured substantially increased cardiovascular disease risk (hazard ratio [95% confidence interval], 5.45 [2.39, 12.42]; P<0.0001), enhanced atherosclerosis progression (median difference in atherosclerosis score [interquartile range], 2.1 [0.8, 5.6] versus 0.0 [0.0, 2.2] mm; P=0.0012), and a trend toward higher levels of oxidized phospholipids on apolipoprotein B-100 (median oxidized phospholipids/apolipoprotein B level [interquartile range], 11364 [4160, 18330] versus 4844 [3174, 12284] relative light units; P=0.0554). Increased cardiovascular disease risk in those homozygous for ≥32 repeats was also detected in a pooled analysis of 7848 participants of the Bruneck, SAPHIR, and KORA prospective studies (hazard ratio [95% confidence interval], 3.26 [1.50, 7.33]; P=0.0043). Conclusions—This study found a strong association between the HO-1 variable number tandem repeat polymorphism and cardiovascular disease risk confined to subjects with a high number of repeats on both HO-1 alleles and provides evidence for accelerated atherogenesis and decreased antioxidant defense in this vascular high-risk group.

[1]  Qingbo Xu,et al.  No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study). , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Jawed Alam,et al.  Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. , 2006, Physiological reviews.

[3]  D. Tarng,et al.  Length polymorphism in heme oxygenase-1 and cardiovascular events and mortality in hemodialysis patients. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[4]  O. Wagner,et al.  Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. , 2002, Thrombosis research.

[5]  F. Kronenberg,et al.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus , 2013, Nature Medicine.

[6]  Qingbo Xu,et al.  Soluble Receptor Activator of Nuclear Factor-&kgr;B Ligand and Risk for Cardiovascular Disease , 2007, Circulation.

[7]  A. Józkowicz,et al.  Role of Heme Oxygenase-1 in Human Endothelial Cells: Lesson From the Promoter Allelic Variants , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[8]  S. Kiechl,et al.  The natural course of atherosclerosis. Part I: incidence and progression. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[9]  F. Kronenberg,et al.  Telomere length and risk of incident cancer and cancer mortality. , 2010, JAMA.

[10]  F. D. Weinfeld,et al.  The National Survey of Stroke. Clinical findings. , 1981, Stroke.

[11]  H. Hashimoto,et al.  Heme Oxygenase-1 Gene Promoter Polymorphism Is Associated With Coronary Artery Disease in Japanese Patients With Coronary Risk Factors , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. , 1979, Circulation.

[13]  S. Shibahara,et al.  Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. , 2000, American journal of human genetics.

[14]  F. Hu,et al.  Short (GT)n repeats in heme oxygenase-1 gene promoter are associated with lower risk of coronary heart disease in subjects with high levels of oxidative stress , 2011, Cell stress & chaperones (Print).

[15]  C. Gieger,et al.  KORA-gen - Resource for Population Genetics, Controls and a Broad Spectrum of Disease Phenotypes , 2005 .

[16]  S. Dabelić,et al.  GT Microsatellite Repeats in the Heme Oxygenase-1 Gene Promoter Associated with Abdominal Aortic Aneurysm in Croatian Patients , 2013, Biochemical Genetics.

[17]  Shing‐Jong Lin,et al.  Serum Bilirubin and Ferritin Levels Link Heme Oxygenase-1 Gene Promoter Polymorphism and Susceptibility to Coronary Artery Disease in Diabetic Patients , 2008, Diabetes Care.

[18]  O. Wagner,et al.  Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. , 2004, Journal of the American College of Cardiology.

[19]  James L. Park,et al.  Heme oxygenase-1 protects against vascular constriction and proliferation , 2001, Nature Medicine.

[20]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[21]  W. Durante,et al.  Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. , 2001, Atherosclerosis.

[22]  F. Kronenberg,et al.  Reproductive factors and its association with peripheral arterial disease in women aged 52-81 years: the KORA F4 study. , 2013, Atherosclerosis.

[23]  E. Hawe,et al.  The microsatellite polymorphism of heme oxygenase-1 is associated with baseline plasma IL-6 level but not with restenosis after coronary in-stenting. , 2005, Chinese medical journal.

[24]  F. Kronenberg,et al.  Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Paul H. C. Eilers,et al.  Flexible smoothing with B-splines and penalties , 1996 .

[26]  A. Uitterlinden,et al.  Fundamental Role for HO‐1 in the Self‐Protection of Renal Allografts , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  O. Wagner,et al.  The effect of a promoter polymorphism in the heme oxygenase-1 gene on the risk of ischaemic cerebrovascular events: the influence of other vascular risk factors. , 2004, Thrombosis research.

[28]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[29]  Aldons J. Lusis,et al.  Network for Activation of Human Endothelial Cells by Oxidized Phospholipids: A Critical Role of Heme Oxygenase 1 , 2011, Circulation research.

[30]  Y. Niida,et al.  Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. , 1999, The Journal of clinical investigation.

[31]  H. Chiou,et al.  GT-repeat polymorphism in the heme oxygenase-1 gene promoter is associated with cardiovascular mortality risk in an arsenic-exposed population in northeastern Taiwan. , 2010, Toxicology and applied pharmacology.

[32]  A. Lusis,et al.  Heme Oxygenase-1 Inhibits Atherosclerotic Lesion Formation in LDL-Receptor Knockout Mice , 2001, Circulation research.

[33]  A. Choi,et al.  Heme oxygenase: colors of defense against cellular stress. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[34]  O. Wagner,et al.  A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease , 2003, Thrombosis and Haemostasis.

[35]  F. Bach,et al.  Heme oxygenase-1: from biology to therapeutic potential. , 2009, Trends in molecular medicine.

[36]  A. Zwinderman,et al.  Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1 , 2006, Pharmacogenetics and genomics.

[37]  David M. Evans,et al.  Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. , 2010, Atherosclerosis.

[38]  F. Kronenberg,et al.  Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. , 2006, Journal of the American College of Cardiology.

[39]  S. Kiechl,et al.  Carotid Atherosclerosis and Incident Atrial Fibrillation , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[40]  F. Kronenberg,et al.  Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. , 2006, Diabetes.

[41]  O. Wagner,et al.  Clinical restenosis after coronary stent implantation is associated with the heme oxygenase-1 gene promoter polymorphism and the heme oxygenase-1 +99G/C variant. , 2005, Clinical chemistry.

[42]  R Holle,et al.  KORA - A Research Platform for Population Based Health Research , 2005, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[43]  A. Kastrati,et al.  Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. , 2007, European heart journal.

[44]  W. März,et al.  Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study) , 2009, BMC Medical Genetics.

[45]  W. Pan,et al.  Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients , 2002, Human Genetics.

[46]  M. Menger,et al.  Vascular Heme Oxygenase-1 Induction Suppresses Microvascular Thrombus Formation In Vivo , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[47]  O. Wagner,et al.  Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism is Associated with Restenosis after Percutaneous Transluminal Angioplasty , 2001, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[48]  S. Kiechl,et al.  Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis. A population-based study. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[49]  T. Morita.  Heme Oxygenase and Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[50]  G. Cooke,et al.  Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.

[51]  A. Lusis,et al.  Vasculitis, Atherosclerosis, and Altered HDL Composition in Heme-Oxygenase-1-Knockout Mice , 2012, International journal of hypertension.

[52]  Ming-Wei Lin,et al.  Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. , 2004, European heart journal.

[53]  O. Wagner,et al.  Haem oxygenase‐1 genotype and cardiovascular adverse events in patients with peripheral artery disease , 2005, European journal of clinical investigation.

[54]  C. Bai,et al.  ResearchShorter GT repeat polymorphism in the heme oxygenase-1 gene promoter has protective effect on ischemic stroke in dyslipidemia patients , 2010 .